Urge your members of Congress to support continued medical research funding
ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2017.
ASH is committed to addressing the burden of sickle cell disease (SCD) and is undertaking a multifaceted initiative to improve outcomes for individuals with
the disease, both in the United States and globally.
As part of the American Society of Hematology’s (ASH)
multifaceted initiative to address the burden of sickle cell disease, ASH is in
the process of working with stakeholders to improve access to care for
individuals with sickle cell disease.
Included in this effort is
A list of major initiatives undertaken by ASH in 2015 with the hopes of increasing education and awareness about sickle cell trait (SCT).
On October 29, 2015, the Centers for Medicare and Medicaid Services (CMS) released a new proposed coverage policy for hematopoietic stem cell transplant for Medicare patients. In May, ASH supported a request made by the National Marrow Donor Program (NMDP) and American Society for Blood and Marrow Transplantation (ASBMT) to change the national coverage determination to explicitly include sickle cell disease and myelofibrosis as well as eliminate the prohibition of coverage for multiple myeloma. CMS has proposed to include coverage for all three of those conditions (for certain indicated patients) under a process called coverage with evidence development.
Join the Grassroots Network to stay up to date on all of ASH’s Advocacy Campaigns.
Become an advocate for hematology with our easy-to-use advocacy resources.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology